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Abstract 
Rationale 
Globally, the prevalence of atopic diseases continues to rise. Up to 20% of the population is 
thought to be affected, exerting enormous health, social and financial burdens. Emerging data suggests 
atopic dermatitis precedes allergic sensitization and may increase the predisposition to food allergy, 
allergic rhinitis and asthma later in life. Pilot testing has suggested infant skin barrier protection may 
reduce the risk of atopic dermatitis. Parallel research has suggested exposure to phthalates may be 
driving the inflammatory process at the dermal level. 
Methods 
The altered skin barrier and hapten-atopy hypotheses are summarized. A schema for a 
pragmatically designed, randomized controlled trial is developed to address: 1.Does skin barrier 
protection using an occlusive moisturizer and measures to reduce phthalate exposure among infants 
reduce the incidence of atopic dermatitis and the prevalence of atopic diseases, and 2.If so, do these 
interventions reduce risk in an additive or synergistic manner? 
Results 
Population based recruitment of newborn infants to one of three interventions or a control arm is 
proposed. The first arm would involve the application of an occlusive skin moisturizer to protect skin 
barrier integrity; the second, measures to reduce dietary and environmental phthalate exposures and the 
third would add skin barrier protection to the phthalate exposure reduction protocol. The protocol phase 
would ideally continue for three years, while the observation phase for the detection of disease incidence 
and prevalence would span 18 years. Recommendations for data interpretation include regression 
analysis for modeling the intervention effects on other environmental and dietary exposures thought to 
increase the risk of atopic diseases. 
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Conclusions 
Pragmatic design would optimize the generalizability of the results. Study findings would clarify 
public health approaches for atopic disease prevention by broadening the current understanding of the 
effects of phthalates on child health and by informing best practices for infant skin care. 
 
Background 
Atopy 
Atopy refers to a tendency to become immunologically sensitized to allergens ubiquitously 
present in the human environment by producing immunoglobulin E (IgE) antibodies against them. 
Allergens are proteins, capable of producing allergic (atopic) diseases in prone individuals. Capacity for 
producing IgE antibodies to allergens is linked to the development of atopic dermatitis (AD), food allergy, 
and allergic anaphylaxis, asthma, and rhinitis (Johansson et al., 2004).  
 
Atopic individuals are likely to develop multiple allergic conditions over the course of their 
lifespan, beginning in childhood (Fleischer, Conover-Walker, Christie, Burks, & Wood, 2003; Peters et al., 
2010). Referred to as the atopic march, clinical manifestation of atopy typically begins with AD. The 
incidence of AD peaks within the first three months of life, followed by food allergy later in infancy, and 
rhinitis and asthma later in childhood (Wahn, 2007). Moderately severe AD among infants is closely 
associated with IgE sensitization to foods (Hill et al., 2007) and children with AD  have 3 times greater 
odds of developing asthma and 2.6 times greater odds of developing rhinitis compared to children without 
AD. Early compared to late onset, and moderate to severe compared to mild AD appear to further 
strengthened the association (early onset OR = 3.44, 95% CI: 1.94-6.09; moderate to severe OR = 3.56, 
CI: 1.62-7.83) (von Kobyletzki et al., 2012).  
 
Prevalence and burden 
Atopic diseases are the most common and earliest onset of the major non-communicable 
diseases and are expected to represent major public health challenges well into the 21
st
 century 
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(Prescott, 2013; von Herttzen & Haahtela, 2004). In high income countries approximately 1 in 5 
individuals are affected (Zheng, Yu, Oh, & Zhu, 2011) with lower socio-economic strata disproportionately 
burdened (Cope, Ungar, & Glazier, 2008; Pawankar, Sanchez-Borges, Bonini, & Laliner, 2011; 
Ruijsbroek et al., 2011). 
 
Atopic dermatitis. AD causes intense itching and chronic, relapsing skin lesions characterized in 
the acute stage by excoriation, inflamed dome-shaped papules and serous oozing and in the sub-acute 
stage by excoriation, papules and lichenified plaques (Leung & Bieber, 2003). Lesions follow a 
predictable distribution; during infancy the cheeks and scalp are usually affected, while in childhood the 
nape, flexure and dorsal limb surfaces are typically involved (Bieber, 2008). Globally, the lifetime 
prevalence of AD is 15 to 30% among children and 2 to 10% among adults (Bieber, 2010). Data from 
Phase III of the International Study for Asthma and Allergy in Children (ISAAC) suggests AD prevalence 
among children ranges from 0.9% in Jodhpur, India, to 22.5% in Quito, Ecuador. In Canada it rests at 
about 10 to 15% (Odhiambo, 2009). In high income countries prevalence rose two to three fold rise over 
the past three decades (Bieber, 2010) but appears to have leveled off, while it continues to rise in middle 
and low income countries (Williams et al., 2008). Overall, the rise as been associated with increasing 
westernization and suggests environmental factors precipitated by socio-economic changes and 
urbanization are important drivers (Bieber, 2010; Romagnani, 2004).  
 
In addition to the risk of future allergic disease, AD exerts considerable socio-economic burdens. 
Families of children with AD must cope with significant emotional effects and limitations on activities of 
daily living (Chamlin, Frieden, Williams, & Chren, 2004). Children with AD appear to suffer more mental 
health disorders compared to children without (Chamlin, 2006) and AD is recognized as having a major 
impact on child and family quality of life (Dodington, Basra, Finlay, & Salek, 2013). The economic costs of 
AD are considerable. Estimates vary widely, but may be as high as $3.8 billion USD annually in the U.S. 
alone (Mancini, Kaulback, & Chamlin, 2008).  
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Food allergy. Allergic reactions induced by food allergens can range from mild and localized to 
systemic and life-threatening (Lack, 2008). The U.S. National Centre for Health Statistics has estimated 
4% of U.S. children have food allergy. Over the course of the decade ending in 2007, an 18% increase in 
the prevalence of food allergy has been reported (Branum & Lukacs, 2008). Drawing on data from several 
countries, a more conservative estimate suggests an increase in prevalence of 0.60% over the past 10 
years (Ben-Shoshan, Turnbull & Clarke, 2012). Prescott and Allen (2011) have noted while some food 
allergies typically remit in childhood, newer data indicates food allergies may be persisting  later into 
childhood (Mullins, 2007). 
 
Food allergy has a profound impact on health-related quality of life (Avery, King, Knight, & 
Hourihane, 2003). Aside from the intangible costs, the economic costs of food allergy are considerable 
and wide ranging, from burdens on individuals and their families to regulators and healthcare systems 
(Miles, Fordham, Mills, Valovirta, & Mugford, 2005). A recent U.S. investigation estimated the overall 
annual cost of food allergy at $4184 USD per child (Gupta et al., 2013). 
 
Anaphylaxis. Allergic anaphylaxis is an acute, life-threatening systemic reaction (Johansson et 
al., 2004; Sampson et al., 2006). The lifetime prevalence of anaphylaxis is between 0.05 and 2% 
(Lieberman et al., 2006). The most common triggers are food allergens. Anaphylaxis is commonly under 
reported. According to U.S. National Electronic Injury Surveillance System data, 57% of events meeting 
the criteria for anaphylaxis failed to be diagnosed in emergency treatment centres in the U.S. (Phelan 
Ross et al., 2008). While death from anaphylaxis is considered rare, under reporting is likely (Simons, 
2010). 
 
Asthma.  Asthma is an inflammatory disease of the lower respiratory tract that produces airway 
narrowing in response to allergen and non-allergen triggers (Global Initiative for Asthma Executive 
Committee, 2011; Johansson et al., 2004). Prevalence ranges from 0.7% in Macau to 18.4% in Scotland 
(Masoli, Fabian, Holt, & Beasley, 2004). While there is evidence of a reduction in the prevalence of 
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asthma symptoms in a number of high income countries (Weiland & Pearce, 2004), it continues to rise in 
Africa, Latin America and parts of Asia (Pearce et al., 2007). However, Anandan, Nurmatov, van 
Schayck, & Sheikh (2010) suggest reports of declines are derived from data that more accurately reflect 
declines in healthcare utilization and therefore better disease control, rather than declines in actual 
disease prevalence. 
 
Asthma and asthma co-morbidities are associated with significant healthcare costs (Badadori et 
al., 2009). It is also the most common cause of school absenteeism and non-participation in activities that 
support physical, intellectual, and social development among children in the U.S. (Wang, Zhong & 
Wheeler, 2005). Children of lower socio-economic status, particularly in low and middle income countries 
are disproportionately burdened by poor control (Cope et al., 2008; Pawankar et al., 2011; Ruijsbroek et 
al.,  2011). 
 
Hypotheses for the rise in atopic disease prevalence 
Hygiene hypothesis. The hygiene hypothesis proposed by Strachan is one of the most enduring 
theories for explaining the rise in atopic disease prevalence (Alcantara-Neves  et al., 2012; Liu & Leung, 
2006; Strachan, 1989). It posits that a lack of exposure to infectious agents in early childhood, consistent 
with 20
th
 century socio-economic changes, cleanliness behaviours and increasing urbanization, 
predisposes the immune system to a T-helper 2 (Th2) response that favours an atopic rather than a 
toleragenic T-helper 1 (Th1) response to allergens (Elston, 2006). Alfvén et al. (2006) demonstrated that 
children growing up in a farm environment were protected from atopic dieseases later in life. Children 
living in helminth endemic regions and younger children raised in larger families also appear to be 
protected. However, findings are not completely consistent: some studies suggest children growing up on 
farms are paradoxically at greater risk of asthma later in life (Elston, 2006). While life long farm exposure 
may be protective against allergic asthma in adulthood (Douwes et al., 2007), Hoppin et al. (2008) found 
pesticide use on farms was associated with allergic asthma among women who worked on farms, 
particularly those who had grown up on a farm. Endotoxin and fungal spore exposure has also been 
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associated with an increased risk of non-allergic asthma among farmers (Eduard, Douwes, Omenaa, & 
Heederik, 2004). 
 
Altered skin barrier hypothesis. Newer findings suggest AD may not be an atopic condition; 
rather that it predisposes to atopic diseases (Simpson, Eichenfield, Ellis, Mancini, & Paller, 2012). Early 
development of AD precedes the production of IgE antibodies and other atopic diseases (Johansson & 
Bieber, 2002; Kubo, Nagao, & Amagai, 2012; Leung & Bieber, 2003). Recently discovered, filaggrin loss 
of function gene mutations have been strongly linked to the development of AD. These mutations are 
thought to be responsible for a set of skin barrier aberrations that lead to a reduced threshold for 
inflammation within the skin. These aberrations include increased transepidermal water loss (TEWL) and 
increased penetration of substances into the skin, including allergens (Boguniewicz & Leung, 2011; 
Suzuki, Kodama, & Asano, 2011; Kubo et al., 2012). Filaggrin and other related gene mutations, have 
provided a compelling theoretical genetic basis for the atopic march, perhaps before it has even begun 
(Boguniewicz & Leung, 2011). 
 
According to a meta-analysis, filaggrin mutations increase the odds of asthma (OR = 1.48, 95% 
CI: 1.32-1.66) and for AD associated asthma (OR = 3.29, 95% CI: 2.84-3.82) (Rodriguez et al., 2009). A 
subsequent study found evidence of interaction between filaggrin mutations and sensitization to foods as 
a predictor of asthma in children who had AD during infancy (OR = 2.64, 95% CI: 1.7-3.98) (Marenholz et 
al., 2009). Another found increased TEWL, AD and AD severity predicted sensitization to foods, while 
filaggrin mutations did not (Flohr et al., 2013). Indeed, dermal exposure to peanut protein has been 
positively associated with peanut allergy among atopic disease prone children (Lack, Fox, Northstone, & 
Golding, 2004): household peanut consumption (used as a proxy for environmental peanut exposure) 
predicted peanut allergy in a dose-response manner, but only when infants did not consume peanut 
products orally (Fox et al., 2009). 
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Hapten-atopy hypothesis. The hapten-atopy hypothesis suggests synthetic compounds are 
acting as adjuvants at the dermal level to potentiate the atopic inflammatory response (McFadden, 
Dearman, White, Basketter, & Kimber Il,  2011; Takano et al., 2006). Adjuvants are low molecular weight, 
mostly electrophilic compounds that bind to proteins to form haptens, thereby rendering the proteins more 
allergenic (Beltrani, Bernstein, Cohen, & Fonacier, 2006; Dudeck et al., 2011; Gittler, Krueger, & 
Guttman-Yassky, 2013). Utilizing a mouse model, Scharschmidt et al. (2009) found the presence of 
filaggrin mutations further reduced the threshold for an inflammatory response to haptens. 
 
A range of synthetic compounds are added to a vast array of consumer products to impart 
fragrance, shelf life, reduced surface tension and plasticity (Jones, 2008). Many may be acting as 
adjuvants, including phthalates (Takano et al., 2006). Phthalates, a class of plasticizing agents, are added 
to personal care products, cosmetics, polyvinyl chloride, children’s toys (Bornehag et al., 2004; Petersen 
& Breindahl, 2000), cleaning agents, insecticides, building materials, furniture, clothing, pharmaceutical 
products and consumer packaging (Schettler, 2005). These diesters of benzenedicarboxylic acid remain 
chemically unbound when added to substances and thus leach into the surrounding environment, 
including food and water (Duty, Ackerman, Calafat, & Hauser, 2005; Schettler, 2005), particularly when 
exposed to high temperatures (National Research Council, 2008). Phthalate exposure occurs through 
oral, respiratory, dermal and parenteral routes. Food contaminated with phthalates from packaging is 
thought to be the primary exposure pathway (Koniecki, Wang, Moody, & Zhu, 2011). For more 
background on phthalates in Canada, see Appendix A: Phthalates. 
 
Exposure to phthalates has increased dramatically since World War II (Bornehag et al.,2004). 
The rise in phthalate exposure correlates well with the rise in atopic disease prevalence (McFadden, 
2010). Now considered to be wide spread, there is good evidence infants are exposed to a number of 
phthalates early in life (NRC, 2008).  
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Phthalates—a population health concern 
Children are disproportionately affected by chemical exposures due to their developing organs, 
high metabolic rate (National Center for Environmental Research, 2007; NRC, 2008) and innate 
exploratory hand-to-mouth and floor play behaviours (Duty et al., 2005; Sathyanarayana et al., 2008). 
There is compelling evidence synthetic chemicals are contributing to a range of unanticipated chronic 
diseases that begin in childhood (Galvez, Forman & Landrigan, 2005; Wang et al., 2005). Indeed, it is 
well accepted population health has been compromised by a historical orientation to a risk management 
approach for judging safety. In the absence of sufficient evidence of harm to health, the approach has 
placed the burden to proof of harm on the shoulders of regulators. As a result, many substances 
suspected of causing harm remain in use (Briand, 2010). 
 
Regulatory changes favouring greater health and environmental protection have emerged since 
the United Nations adopted the precautionary principle (United Nations, 1992). The precautionary 
principle is a framework intended to promote healthy policy decision making. In essence, it places 
emphasis on taking action to protect population health in the absence of certainty (Gilbert, 2005). 
Fundamentally, it places responsibility for proof of safety within the manufacturer’s jurisdiction (Whiteside, 
2006). In Europe for instance, where the precautionary principle has being widely adopted, it has 
contributed to a successful ban on the importation of genetically modified crops (Whiteside, 2006). In 
Canada, the 2006 adoption of the Chemical Management Plan by the federal government represents a 
shift towards a regulatory approach in keeping with the precautionary principle (Briand, 2010). Whiteside 
(2006) elaborates that the precautionary principle importantly facilitates greater public participation in the 
regulatory decision making process and is provoking a demand for better science. He draws on work by 
Ulrich Beck (1992) who explains the evolution of society towards greater individualization and further 
away from collective goals, self-determination to protect against threats to well-being will intensify and 
thus reinforce the precautionary approach. Within this context, research that helps to reveal risks to the 
public may have greater potential to drive change in favour of stronger public health policies, particularly 
when disseminated and deliberated over in an open and accessible manner. 
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Indeed the role of phthalates to explain the rise in chronic disease is a critical and evolving public 
health issue and should prompt additional attention (McFadden et al., 2011). While phthalates are known 
for their negative effects on the developing endocrine system (Bornehag et al., 2004; Petersen, & 
Breindahl, 2000), they remain largely unexplored for other health effects at normal exposure levels 
(Koniecki et al., 2011). In support, European Academy of Allergy and Clinical Immunology has highlighted 
identification of causes for the rise in atopic disease prevalance, including the role of the skin barrier and 
environmental factors as major unmet needs in the atopy research arena (Papadopoulos et al., 2012). 
 
Pathogenic basis for a research schema 
AD stems from a defective skin barrier 
The barrier function of skin, including water holding capacity, continues to develop after birth 
(Nikolovski, Stamatas, Kollias, & Wiegand, 2008). It is thought to function just above the threshold for AD 
at birth. In contrast, among infants with a predisposition to AD, it begins below this threshold and may 
take two and a half to three years to reach or surpass it (Cork et al., 2009).  
 
A healthy epidermal (outer) layer of skin protects against pathogen, irritant and allergen 
penetration (Boguniewicz & Leung, 2011). The stratum corneum (SC), the outermost layer of the 
epidermis, serves as an interface and first barrier between the external environment and the fluid 
environment within the skin. The integrity of the SC is maintained through the constant regeneration of 
keratinocyte layers formed by stratum granulosum (SG) cells (Kubo et al., 2012). Filaggrin is a functional 
protein critically involved in this process. Produced within SG cells, filaggrin acts to collapse and compact 
maturing keratinocytes (Dale, Presland, Lewis, Underwood, & Fleckman, 1997; Roelandt, Heughebaert, & 
Hachem, 2008). Collapsed keratinocytes introduce a lipid rich gel-like mortar into the intercellular space, 
creating a tight, yet flexible protective outer SC layer. The mortar contains ceramides, cholesterol, 
cholesterol esters and fatty acids (Cork et al., 2009). Filaggrin itself is subsequently degraded into 
substances that acidify and hydrate the upper layer of the SC (Boguniewicz & Leung, 2011; Cork et al., 
2009). Using data collected from a cohort of infants selected from the general population, of which 24.9% 
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had AD, Flohr et al. (2013) found filaggrin mutations predicted higher TEWL and were associated with 
more severe AD: the odds for AD among those with, compared to those without, the mutation were 
strikingly higher (OR = 3.55, 95% CI: 2.16-5.84). 
 
AD stems from a defective immune response 
There is evidence of an altered dermal immune response among individuals at risk of developing 
AD. Langerhans cells (LC), a class of dendritic cell, belonging to the innate immune system act to detect, 
engulf and present allergens and haptens to the adaptive immune system T-cells (Gittler et al., 2013). 
Under normal conditions, the LC remain situated below the tight junction layer within the SG. Once 
activated, LC are capable of triggering naïve lymphoid T-cells to mature into Th2 cells, which serve to 
perpetuate the atopic pro-inflammatory response (Werfel, 2009), see Figure: Atopic dermatitis stems from 
a defective immune response. 
 
Chemical or mechanical disruption of the SC stimulates keratinocytes to produce cytokines; 
including thymic stromal lymphopoietin (TSLP)—a potent pro Th2 chemokine (Soumelis et al., 2002), 
which has been described as the link between innate and adaptive immunity (Ma et al., 2009). TSLP is 
not present in either adjacent normal skin or intact AD skin (Soumelis et al., 2002). The production of 
TSLP appears to be predicted by variations in TSLP gene expression (Harada et al., 2009). TSLP 
activates the LC to penetrate the tight junctions within the SG towards the external environment in order 
to engulf allergens, triggering the LC to release the Th-2 pro-inflammatory cytokines that induce T-cell 
maturation into Th-2 cells (Ito et al., 2005). Th-2 cells in turn produce the adaptive immune system pro-
inflammatory cytokines associated with AD, including; Interleukin- 4 (IL-4), IL-13 and IL-31 (Neis et al., 
2006; Werfel, 2009). In lymphoid tissue, IL-4 and IL-13 mediate B-cell production of allergen specific IgE 
antibodies (Werfel, 2009). The cytokines IL-4, IL-13 also act to up-regulate keratinocyte TSLP production 
(Gittler et al., 2013) and inhibit filaggrin production (Howell et al., 2009), while IL-31 may mediate itch 
(Werfel, 2009). The net result includes exacerbation of TEWL (Gittler et al., 2013). 
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Atopic diseases
Pathogen clearance 
Allergens & haptens
LC penetrate tight Junctions (TJ) 
to engulf allergens & haptens
A
B
Cytokines
IL-4 & IL-13
LC activation by 
TSLP
Chemokines, e.g. TSLP
 Figure: Atopic dermatitis stems from a defective immune response. A. In the setting of skin barrier disruption, TSLP activates 
langerhans cells (LC) to penetrate the tight junction layer to detect and engulf allergens and haptens that have entered the stratum 
corneum (SC), B. triggering naïve T-cells in lymphoid tissue to mature into Th2 cells which perpetuate the pro-topic inflammatory 
response. Th2 cells produce the cytokines IL-4 and IL-13 which mediate B-cell production of allergen specific IgE antibodies. 
Diagram A. An adaptation of a figure reproduced with permission [for educational use] from Kubo, Nagao & Amagai (2012), 
Copyright Journal of Clinical Investigation. Diagram B. An adaptation of a figure reproduced with permission [for educational use] 
from Bieber, 2008, Copyright Massachusetts Medical Society. 
 
 
These recent findings, from filaggrin mutations to variations in TSLP gene phenotypic expression, 
lend support to speculation that multiple factors are driving atopic responses to environmental stimuli. 
Furthermore, that genetic and environmental factors may be acting either additively or synergistically to 
increase risk for AD (Kubo et al., 2012). 
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Evidence from skin barrier protection studies 
A clinic-based pilot study has been undertaken by Simpson, Berry, Brown and Hanifin (2010) to 
explore the feasibility of using an occlusive skin moisturizer to enhance the skin barrier integrity among 
infants at risk for AD. Expectant mothers were continuously recruited from the prenatal and dermatology 
clinics of a university health centre if their unborn infant had either a parent or related sibling with AD and 
one parent or sibling with either allergic asthma or rhinoconjunctivitis. The investigators noted that these 
infants were expected to have a 30 to 50% chance of developing AD by two years of age according to 
Hoare, Li Wan Po and Williams (2000). A petrolatum based (oil/grease>water) moisturizer was applied 
once daily to skin surfaces of the newborn infants starting at one to seven days of life. Findings included 
85% compliance at 24 months of age and no adverse effects. TEWL and skin capacitance remained 
within normal limits, see Appendix B: Transepidermal water loss and skin capacitance measurement. The 
AD incidence rate was 22.7% at 18 months according to intention-to-treat analysis. These results were 
considered promising given the high predicted incidence among the infants recruited (Simpson, Berry, 
Brown, & Hanifin, 2010). Moisturizer use among infants with healthy skin also leads to reduced TEWL 
(Telofski, Morello III, Correa, & Stamatas, 2012). Many caregivers use moisturizers to treat infant skin 
regardless of whether AD is present, however as few as 12-15% attending a university based 
dermatology practice used thick (oil/grease> water) products with occlusive barrier properties capable of 
reducing TEWL (Rendell et al., 2011). Thus a skin barrier protective protocol using an occlusive 
moisturizer appears effective for reducing TEWL, and most likely represents a departure from 
conventional infant skin care practices. The selection of skin moisturizers available in the retail market is 
vast; not all products are equally effective or safe for infant use. Some contain phthalates (Duty et al., 
2005; Sathyanarayana et al., 2008) as scent stabilizers (U.S. Department of Health & Human Services, 
2013a), humectants and emollients (Hubinger & Havery, 2006).  
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Phthalates as drivers of AD inflammation 
Evidence suggests prolonged, repeated, low dose exposures to adjuvants promotes a Th2 
dominant response in the skin precipitated by TSLP (Hirasawa et al., 2009) and involves LC, 
keratinocytes, and other Th2 cells (McFadden et al., 2011). 
 
In the mouse model diisononyl phthalate (DINP) was found to activate dendritic cells, induce 
TSLP production and aggravate AD in the presence of dust mite allergen. The dose that provoked the 
most prominent response was at the no observable adverse effect level (NOAEL) for general chronic oral 
toxicity and 6.5 to 12.5 times below the NOAEL for developmental toxicity in rats (Koike et al., 2010). Di-
(2)-ethylhexyl phthalate (DEHP), at a dose 100-fold lower than the NOAEL, also aggravated AD, and 
increased the concentration of Th2 cytokines and Th2 cells in AD lesions (Takano et al.,  2006). DEHP 
injected into lactating mice enhanced the AD lesions in their off-spring. The aggravating dose was also 
several folds lower than the NOAEL (Yanagisawa et al., 2008). Other teams have also demonstrated the 
Th2 cascade precipitated by TSLP is enhanced by exposure to dibutyl phthalate (DBP) (Larson et al., 
2010; Shigeno, Katakuse, Fujita, Mukoyama, & Watanabe, 2008). While these studies explore the effects 
of individual phthalates, there is a significant data gap regarding the effects of cumulative exposures to 
phthalates and the most vulnerable periods of development (NRC, 2008). 
 
Studies of the effects of phthalates on atopic disease development in humans are limited 
primarily to observational studies of environmental exposure. von Kobyletzki et al. (2012) found a positive 
association between polyvinyl floor coverings and the incidence of rhinitis among children with eczema, 
(OR = 1.6, 95% CI: 1.02-2.51) and Carlstedt, Jönsson and Bornehag (2013) demonstrated polyvinyl 
flooring in homes was predictive of butylbenzyl phthalate (BBP) metabolites in infant urine. Bornehag et 
al. (2004) showed a positive relationship between BBP in dust samples and AD and rhinitis prevalence, 
and between DEHP and asthma and in atopic children. Kolarik et al. (2008) and colleagues found a 
positive relationship between the use of furniture cleaning agents and less frequent dusting (less than 2 to 
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3 times per week) and BBP, but not DEHP concentration in household dust, suggesting cleaning habits 
may reduce or alter phthalate exposure. 
 
Dietary studies have been limited to exploring sources of phthalates and to test if interventions 
may be employed to reduce exposure. Data collected for the 2003 to 2004 U.S. National Health and 
Nutrition Examination Survey suggested dietary intake of poultry, tomato and potato positively predicted 
urine phthalates, while higher fruit consumption was a negative predictor (Colacino, Harris, & Schecter, 
2010). In a study designed to explore infant phthalate uptake, Carlstedt et al. (2013) found formula 
feeding predicted higher urine levels of DEHP with evidence for a dose response relationship. In an 
interventional study, the effect of a five-day adherence to routine Buddhist practices including a 
vegetarian way of eating, produced significant reductions in phthalate exposure as determined by urine 
phthalate levels (Kyunghee, Kho, Park, & Kyungho, 2010). Rudel and colleagues showed phthalate 
ingestion can be reduced by avoiding food packaging and pre-prepared foods. Twenty individuals, 
including children, were provided with beverages and pre-prepared foods made from fresh, organic 
ingredients without the use of plastic utensils and containers. Post intervention urine phthalate was 
approximately 50% lower compared to pre-intervention levels (Rudel et al., 2011). In contrast, 
Sathyanarayana et al. (2013) found in another dietary intervention study, designed to reduce phthalate 
exposure through the provision of catered foods prepared from fresh and organic ingredients that 
phthalate exposure was paradoxically increased due to unexpected dairy product and spice 
contamination of the catered foods. 
 
Routine infant skin care is also an important source of phthalate exposure (McFadden, 2010). 
Duty et al. (2005) found parent reported use of infant powder, lotion and shampoo predicted urinary 
excretion among infants, (OR = 2.1, 95% CI: 1.3-3.6; OR = 2.1, 95% CI: 1.3-3.4; OR = 1.6, 95% CI: 1.02-
2.4, respectively). A dose response relationship was detected according to the number of skin care 
products used. The associations were stronger among infants younger than eight months of age 
(Sathyanarayana et al., 2008). Questions have been raised whether moisturizers would enhance rather 
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than inhibit the transmission of chemicals though the skin (Rice et al., 2003). Duty et al. (2005) found 
moisturizer use was associated with lower urine phthalate levels, but cautioned there is insufficient 
evidence to support a causal relationship. 
 
Proposed research question 
 Knowledge of the possible underlying mechanisms involved and the relationship between skin 
barrier defects, phthalate exposure and AD development among infants suggests new research questions 
should be generated in order to develop existing hypotheses to explain the atopic march during different 
phases of the life-course. Furthermore, the health protection regulatory environment has shifted to being 
more conducive to uptake of research that reveals new questions about the safety of phthalates that may 
lead to effective interventions to reduce the hazard, thus intensifying the public health practice value of 
such research. The research schema that follows is designed to address the questions: Does skin barrier 
protection using an occlusive moisturizer and measures to reduce phthalate exposure among infants 
reduce the incidence of AD and the prevalence of atopic diseases later in life? If so, do these 
interventions reduce risk in an additive or more synergistic manner? 
 
Experimental design considerations 
Ethical considerations 
To be ethical, research involving infants and children must balance, the principle that children 
should be protected from the potential risks of research and that they should not be excluded from the 
potential benefits of participation. Achieving this balance is one of the most challenging issues facing 
research. Interventions must be sufficiently rigorous to answer the research question posed and ensure a 
reasonable level of hope that they will contribute to a better understanding of disease prevention. This 
means a study must be adequately powered, free of important biases and lead to valid conclusions. 
Infants should only be recruited if the study of older individuals would fail to address the question. 
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Subjects should be representative of the children at risk so that the results are generalizable to the 
population the research has potential to help (Diekema, 2009). 
 
Efforts must be made to minimize the risks of participation (Diekema, 2009). Minimal risks to 
healthy infants (before there is evidence of disease) is defined as risk of harm or discomfort no greater 
than the “probability and magnitude…ordinarily encountered in daily life or during the performance of 
routine physical…examinations or tests” (Interagency Advisory Panel on Research Ethics, 2011; U.S. 
Department of Health and Human Services, 2009). When risk is greater than minimal, the benefits must 
be balanced against the potential harms (IAPRE, 2011). 
 
Given AD can begin in early infancy and the vulnerability to phthalates is also likely to be greatest 
during early life, recruitment of infants according to the following schema is justifiable. The potential risks 
are limited to those encountered during serial, mostly non-invasive physical examinations. Other indirect 
risks include possible burdens to their parents due to extra work resulting from protocol implementation 
and frustration related to limitations on food, skin care and household cleaning product selection. On the 
other hand, infants whose exposure to phthalate is experimentally reduced may benefit beyond possible 
reduction in AD incidence, given the potential of phthalates to adversely affect health though other 
pathways, such as reproductive development (Engel et al., 2009; Swan et al., 2005). Potential benefits to 
infants enrolled include; earlier detection of AD, attenuation of AD related psychological abnormalities 
(Chamlin et al., 2004) and improved health-related quality of life in both subjects and their caregivers 
(Lewis-Jones, Finlay & Dykes, 2001; Paller & Chren, 2012; Dodington et al., 2013).There is also the 
possibility of a positive impact on parent-infant bonding stemming from the skin barrier protection protocol 
(Blume-Peytavi et al., 2009). 
  
ATOPIC DISEASE PREVENTION— A RESEARCH SCHEMA FOR EVALUATING SKIN BARRIER 
PROTECTION AND PHTHALATE EXPOSURE REDUCTION     17 
 
LINDA KIRSTE 
A case for a pragmatic schema 
Controlled intervention trials may be viewed as either pragmatic or explanatory. Purely pragmatic 
trials test whether “real world conditions” produce the desired effect (Thorpe et al., 2009). Following are 
some key characteristics of a pragmatically oriented research design: 
 
− Participants recruited possess a range of risks for the condition of interest, and expected levels of 
protocol adherence and will vary among them (and the study is powered sufficiently to detect 
clinical differences given participant diversity), 
− Investigators encompass a range of disciplines with a range of skills and experiences, 
− There is flexibility in how and where the intervention is applied, 
− The intervention is unobtrusive without measurement of compliance and without the employment, 
of strategies to promote adherence, 
− The control arm involves usual practice rather than a placebo, 
− Follow-up visits are informal and involve databases for outcome detection s, 
− The primary outcome is measured and clinically meaningful to participants, 
− Practitioner adherence to the protocol is either not measured or unobtrusive, and 
− Analysis is according to intention-to-treat (Thorpe et al., 2009). 
 
While very few trials are either purely pragmatic or explanatory in design, the primary advantages of a 
pragmatic orientation is that it tests whether the intervention will work under usual, rather than ideal 
conditions (Thorpe et al., 2009), hence the more pragmatic the design the better study is able to address 
whether the intervention is effective, rather than merely efficacious (Porzsolt, Eisemann, Habs, & Wyer, 
2013). 
 
Interventions 
An experimental approach is a suitable means for exploring the effects of skin barrier protection 
and reduced phthalate exposure. The fundamental reasons include that existing exposure levels to 
phthalates may be above the levels thought to potentiate the Th2 response, thus limiting the utility of an 
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observational design. Likewise, given current allergy prevention recommendations do not include 
guidance on skin barrier protection, current infant skin care practices are likely insufficient to optimize skin 
barrier integrity according to a limited evaluation of children attending a dermatology clinic (Rendell et 
al.,2011). Drawing on a population-based sample, randomly assigned, three interventions along with a 
control arm should be considered; where the first involves skin barrier protection measures that can be 
incorporated into routine infant care, the second phthalate exposure reduction practices, and the third 
involves adding the skin barrier protection protocol to the phthalate reduction measures. The control arm 
would enable detection of differences in outcomes that can be attributed specifically to the protocols, 
rather than to study participation. 
 
Protocol development and implementation 
Each protocol would require substantial development by a multidisciplinary team to ensure it is a 
valid, practical and safe. This may involve pilot testing. Implementation should also involve development 
and delivery of an effective, standardized parent education programme to support protocol adherence 
(Bieber, 2010; Futamura, Masuko, Hayashi, Ohya, & Ito, 2013; Nicol, 2011; Sathyanarayana et al., 2013). 
Mid-intervention phase education to support adherence should be justified so that external validity is not 
unduly compromised (Porzsolt et al., 2013). This may be accomplished by limiting education to the 
frequency that could be realistically incorporated into routine prenatal and well-infants visits (Thorpe et al., 
2009). 
 
Skin barrier protection protocol considerations. Development of the skin barrier protection 
protocol would involve selection of an appropriate occlusive skin moisturizer and specification of all 
aspects of infant skin care (Blume-Peytavi et al., 2012). Any moisturizers considered should be phthalate 
free and as inert as possible. Pure petrolatum is a non-sensitizing (Tam & Elston 2006), widely used 
moisturizer with occlusive properties (Kraft & Lynde, 2005; Nolan & Marmur, 2012). It is capable of 
reducing TEWL to near normal levels (Ghadially, Halker-Sorenson, & Elias, 1992), even at concentrations 
of 5% (Lynde, 2001). Occlusives introduce a hydrophobic layer on the skin surface thereby inhibiting SC 
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water loss. They also penetrate the SC promoting the production of intercellular lipids (Grubauer, G., 
Feingold, K.R. & Elias, P.M., 1987), which facilitate restoration of skin barrier function (Ghadially et al., 
1992). They are particularly effective when applied directly after a bath (Telofski, L.S., Morello III, P.M., 
Correa, M.C.M. & Stamatas, G.N., 2012). For more background on petrolatum-based moisturizers, see 
Appendix C; Petrolatum-based moisturizers. Consideration should be given to pilot testing the effect of 
products under consideration on infant urine phthalates levels and to confirm absence of other harmful 
exposures. Other important moisturizer product selection criteria should include manufacturer’s proof of 
safety, accessibility in retail markets, cost and aesthetical appeal to parents (Simpson et al., 2010). Other 
criteria include demonstration each individual ingredient and the product as a whole is neither irritating 
nor sensitizing. Products should be resistant to bacterial growth and be packaged in a manner that 
minimizes bacterial, as well as, chemical contamination (Telofski et al.,2012) 
 
Phthalate exposure reduction protocol considerations. The phthalate exposure reduction 
protocol should address exposures resulting from infant skin care products, clothing, diapers, furniture, 
toys, bottles and feeding utensils, family skin care products, meals, and eating and drinking containers, 
food preparation utensils and storage containers, household cleaning products and practices and contact 
with parents’ skin care products through towels and bedding. Thought should be given to ensuring study 
participants do not incur additional costs by implementing the protocol. 
 
Development of a low phthalate diet for mothers, infants, and by extension the whole family, 
would be no small task and must balance meaningful reduction in exposure with minimal interference with 
normal dietary and meal planning routines to be efficacious. Low phthalate diet design criteria should 
include strategies for replacing foods sold and stored in cans and plastic with a wide range of alternate 
easy to prepare food choices and storage options. A low phthalate diet education programme should 
encompass parental coaching as well as instruction and the provision of supportive print and electronic 
resources. Current theory driven education approaches and on-line tools for promoting diet adherence 
may serve as useful models (Sainsbury, Mullan, & Sharpe, 2013). Valid design and implementation of the 
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diet may be aided by pilot testing. While the phthalate reduction protocol as described represents a 
significant departure from pragmatic design principles, it will optimize the efficacy of the intervention and 
thus strengthen the case for removal of phthalates from consumer products. 
 
Inclusion criteria 
Inclusion criteria should be limited to healthy term infants from a population unselected for AD risk 
to avoid over burdening infants and children already affected by illness (Diekema, 2009). Given the high 
prevalence of atopic diseases (Zheng et al., 2011), children without identifiable risk of AD during 
screening may stand to benefit from enhanced barrier protection and reduced phthalate exposure. While 
this will increase the number needed to recruit, it follows a pragmatic approach to study design. 
Furthermore, selection based on AD risk is problematic: neither parental history of atopy nor genetic 
testing for filaggrin mutations is very sensitive (Arshad et al., 2012). For instance, recruitment from within 
urban centres in Canada, will likely include some migrants from geographical regions of lower atopy 
prevalence. As a result, some infants at risk will not be identifiable based on parental history (Rottem, 
Szyper-Kravitz, & Shoenfeld, 2005). 
 
Recruitment 
Site. Generalizability of outcomes is likely favoured by a multicentre recruitment approach 
(Gheorghe, Roberts, Ives, Fletcher, Calvert, 2013). While more than one site complicates study 
administration, it supports representativeness of findings to a range of levels of urbanization, socio-
demographic status, living conditions and climates. Randomization to interventions and control arms 
should thus occur within, not between centres. 
 
Sample frame. Sampling is likely to be facilitated by recruiting expectant mothers wherever they 
may visit routinely for well pregnancy care, including; public health units and centres, family practitioner, 
nurse practitioner and midwifery practice offices, as well centres for prenatal diagnostic testing. 
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Recruitment should occur throughout the year to avoid over representation of infants exposed to AD risk 
factors dependent on time of year. 
 
Study duration 
Three years from birth may be considered an optimal endpoint for the protocol phase given the 
age at which normal skin barrier function is reached among children with a predisposition to mild AD 
(Cork et al., 2009). The decision on the optimal endpoint for long term outcome monitoring should be 
based on natural history studies of atopic disease onset and the intervals of measurement adopted by 
other longitudinal intervention studies to facilitate outcome comparisons. This would suggest a duration of 
six (Liu, Martinez, & Taussig, 2010) to 18 years after the final participant is recruited: the Isle of Wight 
dietary allergen and house dust mite intervention study for instance monitored participants up to 18 years 
of age (Arshad, Bateman, Sadeghnejad, Gant, & Matthews, 2007; Kurukulaaratchy et al., 2012; Scott et 
al., 2012).  
 
 Monitoring 
Adherence. Adherence monitoring should encompass all aspects of the protocols parents are 
asked to carry out. Protocol specific validated questionnaire instruments administered by an interviewer at 
specified time intervals during the intervention phase offer advantages over self-administered tools for 
completion rate (Neuman, 2006) and can predict adherence (Dunbar-Jacob, Sereika, Houze, Luyster, & 
Callan, 2012). An explanatory design approach to adherence monitoring should be considered for the 
phthalate reduction protocol. Adherence data may be used to offer feedback to participants to support 
adherence. Measurement of adherence to the dietary intervention may be undertaken using food 
frequency questionnaires (Rice et al., 2003). This method though subject to recall bias, may offer a better 
estimate of mean phthalate intake compared to 24-hour recall and duplicate diet analysis, given variability 
in food choices from day to day (NRC, 1993). 
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Primary outcomes. Short term. Cumulative incident AD and severity of AD between intervention 
and the control groups may serve as optimal primary outcome measures. Ascertainment would be best 
supported by direct physical examination by research assistants with standardized training and blinding to 
treatment (Simpson et al., 2012). 
 
Unfortunately, a precise definition for incident AD has yet to be well defined (Simpson et al., 
2012). Existing definitions are better suited for diagnosing pre-existing disease. For example, Simpson et 
al. (2012) note the Hanifin-Rajka criteria include “relapsing and remitting course”, and the UK Working 
Party criteria include “itchy skin condition in the past 12 months”. Therefore these definitions are ill suited 
for detecting new-onset cases. They have proposed a definition for incidence cases based upon the UK 
Working Party criteria for AD in which the duration criterion for symptoms is four weeks, see Appendix D: 
Proposed definition of incident AD. 
 
A 2007 systematic review revealed only a few instruments have been developed for measuring 
disease severity. These include the Severity Scoring of Atopic Dermatitis Index (SCORAD), the Eczema 
Area and Severity Index (EASI) and the Patient–oriented Eczema Measure (POEM). All three have been 
adequately validated (Schmitt, Langan, & Williams & The European Dermato-Epidemiology Network, 
2007). Work by the Harmonizing Outcome Measures for Eczema (HOME) initiative, an interdisciplinary 
group of global reach mandated to promote the advancement of eczema outcomes research (Schmitt et 
al., 2012), is a potential resource to assist with further refinement of a definition for AD severity. 
 
Long term. Cumulative incidence and prevalence of other atopic diseases would serve to assess 
study outcomes longitudinally. Measurement of environmental allergen sensitization is also a useful 
predictor of atopic disease. Total house dust mites serum IgE antibodies for instance of 0.20kU/L at two 
years of age offered a 86.1% PPV and of 0.35kU/L at five years of age a 93.3%PPV for wheezing—an 
indicator of asthma (Holt et al., 2010). The definition of asthma is also complicated by phenotypic 
differences in disease expression. Case ascertainment would involve establishment of a measurement 
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protocol that accounts for these differences (Soto-Ramírez et al., 2013). Evidence of persistent wheezing 
rather than intermittent wheezing during the first six years of life was most predictive of asthma by 16 
years of age, according to data on wheezing gathered from parental report for the Tucson Children’s 
Respiratory Study (Martinez et al., 1995; Morgan, 2005). 
 
First year of life incidence and subsequent prevalence of peanut allergy to five years of age may 
serve as useful indicators of food allergy. Peanut allergy may be measured according to a protocol 
described by Roberts and Lack (2005) in which parent reported signs of acute allergic reactions after 
peanut ingestion were validated either by skin prick or food specific serum IgE antibody test. In sum, 
measures of atopic disease indicators and predictors are available to detect differences in incidence and 
prevalence between intervention and control arms in children as early as six years of age.  
 
Secondary outcomes. Skin barrier integrity. Given TEWL predicts skin barrier defects 
associated with AD risk, it may be a useful adjunctive measure of skin barrier protection efficacy. 
Guidelines for measuring TEWL have been described and utilized in other studies (Pinnagoda, Tupker, 
Agner, & Serup,1990). In addition, hydration of the superficial layer of the SC may be assessed by 
measuring skin capacitance (Matsumoto et al., 2007). However, both these measures may lack sufficient 
sensitivity to rule out risk of AD: Simpson et al. (2010) found the skin barrier protection protocol they 
investigated achieved normalization of TEWL and skin capacitance, yet a significant number of infants 
still developed AD. 
 
Phthalate exposure. Cumulative and multiple as well as acute exposure to individual phthalates 
would serve as important variables for comparison between intervention and control groups. Högberg et 
al. (2008) concluded urine concentrations of phthalate metabolites in infant urine are better predictors of 
exposure and less invasive compared to blood and breast milk assays. Furthermore, measurement of 
urine phthalate metabolites may be used to assess exposure changes utilizing relatively small numbers of 
subjects, over short periods of time (Rudel et al., 2011). 
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Other exposures. An array of other exposures should be considered for monitoring during the 
protocol phase. Measurement of these potential co-factors could help determine whether the intervention 
and control groups were homogenous, and whether susceptibility to environmental exposures differs 
between groups. Other exposures include skin irritants, bisphenol A, environmental and food allergens, 
environmental tobacco smoke, household and gastrointestinal microbiomes, breastfeeding, timing and 
choice of weaning foods, nutrition status and climate. For summaries of each of the other exposures 
listed, see Appendix E: Other exposures. 
 
While the experimental design proposed specifically involves measures to reduce phthalate 
exposure, it may be challenging to design a protocol that is phthalate specific: other relevant exposures 
are likely to be reduced as well. For instance, the household cleaning protocol proposed will most likely 
influence house dust mite, pet, pollen and food allergen exposures. Similarly, the skin care protocol will 
likely affect exposure to skin irritants and non-phthalate adjuvants unintentionally by virtue of specifying 
the skin care products for use. Other exposure measurement strategies should also be designed to 
measure changes during the invention phase: specific infant care and household cleaning practices for 
instance may be stopped, started or substituted during the trial. 
 
Other outcomes. Adverse reactions to moisturizers. While no adverse events related to long 
term use of appropriate (and phthalate free) moisturizers have been identified (Simpson et al., 2010; 
Telofski et al., 2012), monitoring for adverse outcomes will enable characterization of the risk benefit 
relationship of the skin barrier protection protocol in relation to unspecified products used in the control 
arm and thus should be monitored. 
 
Growth and other health outcomes. Growth velocity and attainment of adult stature is closely 
tied to nutrition and overall health (Garza & de Onis 2007). An increased incidence of skin infections is 
associated with AD (Liu et al., 2010; Novak & Leung, 2010) and an increased rate of lower respiratory 
tract infections have been linked to asthma (Kusel et al., 2007). Thus monitoring of growth and cumulative 
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incidence of infection may provide additional data for outcome evaluations. Consideration may also be 
given to monitoring of neurological and endocrine health to address the possibility of addition protection 
against disorders associated with phthalate exposure.  
 
Genetic screening. Screening for filaggrin mutations would serve as an additional criterion for 
evaluating for homogeneity between intervention and control groups. It would also enable sub-group 
analysis of intervention effect according to AD risk (Kawaski et al., 2011). Genetic screening however has 
ethical implications. The psychological and social impacts of predicting future risk of disease should be 
considered (Geller, 2005; van El & Cornel, on behalf of the ESHG Public and Professional Policy 
Committee, 2011). Thus a separate consent process if genetic screening is considered may be desirable. 
Screening may be done with minimally invasive cheek swabs at anytime during the outcome monitoring 
phase with consideration given to an age at which child maturity facilitates informed consent and optimal 
coping with screening outcomes. 
 
Psychological and health-related quality of life outcomes. Given the major impact of AD on 
health-related quality of life, measurement of differences between intervention and control groups should 
be considered to detect the psycho-social effects of the interventions. The Dermatitis Family Impact 
questionnaire and the Infants’ Dermatitis Quality of Life Index (suitable for children to six years) are 
reliable and widely used instruments for measuring health-related quality of life outcomes that may be 
considered for use (Lewis-Jones et al.,2001; Van Valburg et al., 2011; Dodington et al., 2013). 
Unexpected positive outcomes may also occur within the psychological domain stemming from the skin 
barrier protection protocol. Infant bathing involves touch, is considered soothing and promotes bonding 
between infant and caregiver (Blume-Peytavi et al., 2009). Whether psychological benefits can be 
realized from the skin barrier protection protocol may be worthy of evaluation. Validated questionnaire 
instruments for consideration include the Maternal Postpartum Attachment Scale, the Postpartum 
Bonding Questionnaire and the Mother-to-Infant Bonding Scale. All three measure emotional bonding 
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between a mother and her infant up to approximately six months of age (van Bussel, Spitz, & 
Demyttenaere, 2010). 
 
Analysis 
Differences in cumulative incidence of AD and age prevalence of severity between intervention 
and control groups at defined participant ages may be compared using odds ratios of disease (Szklo & 
Nieto, 2007a). Given two interventions are being tested separately and together, it is also possible to test 
for additive and synergistic effects (Szklo & Nieto, 2007b). 
 
Analysis of secondary outcomes, TEWL, skin capacitance and urinary phthalate levels would 
involve two-way comparisons of means testing between independent samples using a multiple 
comparison procedures and logistic regression to detect differences between the intervention and control 
arms (Pagano & Gauvreau, 2000). Analysis of differences in other exposures between groups may also 
be approached in a similar manner. 
 
Regression analysis may assist to differentiate between the effects of phthalate reduction and the 
protocol effects on other environmental exposures as well as the effect of the skin barrier protection 
protocol on dermal phthalate and irritant exposures (Szklo & Nieto, 2007c). Differences of effect of other 
exposures between interventions may also serve to develop new hypothesis concerning the relationships 
between skin barrier integrity and susceptibility to the Th-2 pro-inflammatory effects of phthalate and 
other environmental and dietary exposures of interest.  
 
Sample size derivation 
Anticipated sample size requirements within intervention and the control groups will depend on 
the expected magnitude and variance of effects within each intervention. Actual sample size calculations 
are beyond the scope of this proposal. Nonetheless, data from other longitudinal studies can assist with a 
preliminary assessment of sample size requirements. Scott at el. (2012) recruited 120 at risk infants 
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divided between intervention and control arms to assess the effect of environmental and dietary allergen 
exposure reduction measures to 18 years of age. The sample was sufficient to detect a difference in 
overall asthma prevalence between one and 18 years of age. The unprecedented subject retention rate of 
100% observed in the study cannot, however, be expected to be replicated in other settings. The 
Canadian Childhood Asthma Primary Prevention Study involved the recruitment of 545 at risk children 
before birth for evaluation post exposure intervention. At seven years 70% (approximately 190 per 
invention or control group) (Chan-Yeung et al., 2005) and at 15 years 60% (Wong et al., 2013) of the 
subjects remained available for evaluation. The average number of at risk children evaluated in nine 
single and multi-intervention environmental allergen exposure trials was 3271 to at least five years of age. 
This also represents an average of approximately 200 children per intervention arm (Maas et al., 2009), 
suggesting at least 200 infants unselected for atopy risk would need to be recruited for a longitudinal 
evaluation from birth to about five years of age. 
  
No research was found to help estimate the anticipated magnitude of change in phthalate 
exposure (as determined by urine levels) necessary to affect a change in AD incidence. Sathyanarayana 
et al. (2008) recruited 163 infants to predict the effect of infant skin care product use on urine phthalate 
metabolite levels, without an intervention arm. Simpson et al. (2010) recruited 20 infants at risk of AD for 
assessment of a skin barrier protection protocol on AD outcomes but did not include a control group. 
More certainty could be added to the 200 plus figure derived from longitudinal studies by conducting 
controlled pilot intervention trials of both proposed protocols. Not only would they serve to develop useful 
data for sample size calculations, they would offer valuable lessons learned to assist with protocol 
refinement. 
 
Implications of positive study findings 
Study outcomes based on the outlined schema would help articulate the role of phthalates to 
explain the incidence and prevalence of atopic diseases and thus serve to broaden scientific 
understanding the effects of phthalates on child health. Furthermore, through the incorporation of 
ATOPIC DISEASE PREVENTION— A RESEARCH SCHEMA FOR EVALUATING SKIN BARRIER 
PROTECTION AND PHTHALATE EXPOSURE REDUCTION     28 
 
LINDA KIRSTE 
pragmatic design principles where rational, the schema would optimize the generalizability of the 
outcomes to the general population. Positive findings derived from the skin barrier protection protocol 
would offer potentially feasible approaches for optimizing best practise approaches to infant skin care 
guidelines disseminated through existing public health channels. Positive findings derived from the 
phthalate reduction arms would strengthen the evidence in favour of legislation to restrict the use of 
phthalates in consumer products, particularly in the context of the recent regulatory shifts in Canada. This 
benefit could accrue with exposure reduction alone even if no relationship to AD is found. 
 
Positive findings would afford an opportunity to leverage (Whiteside, 2006) the precautionary 
principle to facilitate a deliberative process within the public domain to address synthetic compound 
exposures and risk to infant and child health. Knowledge translation and exchange could serve as a 
framework for facilitating this deliberative process (Boyko, Lavis, Abelson, Dobbins, & Carter, 2012). 
Knowledge translation and exchange is a dynamic, iterative process involving the contextualisation and 
integration of study findings into a larger body of knowledge on a subject. It is a systematic means for 
disseminating the findings to a wide audience of citizens, practitioners and policy makers through an open 
process employing a range of media, and is a means for exchange characterized by a collaborative 
problem solving approach between stakeholders and knowledge holders (Canadian Institutes of Health 
Research, 2013). 
 
An “End of Grant KT” approach to dissemination (CIHR, 2013) may be taken, whereby the high 
prevalence and general public interest in atopic diseases is leveraged to focus on the relationship 
between study findings and the population health benefits of increased regulation of phthalates. 
Emphasis could also be directed at inclusion of a wide range of health practitioners and allergy advocacy/ 
interest groups to disseminated skin barrier protection findings especially within the primary and public 
health realms. 
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Schema Limitations 
A major limitation to the proposed schema and common to intervention trials of longer duration is 
the potential for confounding. For example, indirect reduction in irritant and other hapten exposures within 
the skin barrier protection protocol and environmental allergen exposure within the phthalate exposure 
reduction protocol cannot be avoided. Even though regression analysis may help to tease out other 
exposure effects, the risk of colinearity is significant (Szklo & Nieto, 2007c). Considerable work would be 
required to develop the schema into a proposal suitable for funding and ethics applications: this work 
would include pilot testing and derivation of anticipated sample size requirements, as described. An 
estimate of the cost to carry out the schema when adequately powered to provide usable results in each 
of the study arm has not been provided. 
 
Conclusions 
With manifestations starting in infancy, atopic diseases are considerable public health problems 
that include lasting negative effects on healthy child development. While the prevalence of atopic 
diseases has stabilized in high income countries, regions across the globe with fewer resources to cope 
continue to experience rising prevalences. New hypotheses to explain complex disease origins have 
being articulated. The role of skin barrier impairment as a precedent to atopy and the role of phthalates as 
adjuvants of the pro-Th2 inflammatory response are compelling. A randomized, two-protocol, three-
intervention, plus one control arm approach, with emphasis on pragmatic design, may offer a useful 
research schema for investigating the role of skin barrier protection and phthalate exposure reduction 
among infants at risk of atopic disease. A recently modernized chemical regulatory framework in Canada 
has the potential to change the legislative climate in favour of improved responsiveness to new research 
concerning synthetic chemical safety. A knowledge translation and exchange approach to dissemination 
of positive study findings may serve to drive change at the environmental health policy level as well as 
within the public health and primary healthcare domains in favour of risk reduction for AD and other atopic 
diseases. 
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Appendix A: Phthalates 
In 2013, Health Canada revised a list of phthalates for further safety assessment (Government of 
Canada, 2013). While some used in cosmetic and personal care products are being phased out, others 
continue to contribute to the total body burden to which children and infants remain subjected. 
 
Environment Canada identified 14 phthalates for assessment and a further 14 for possible 
assessment over the next five years (Environment Canada, 2013) due to evidence of their adverse 
effects on reproductive system development among male animals (NRC, 2008), see Table 1: Phthalates 
identified for review and possible review by Environment Canada. Much remains to be learned about the 
effects of phthalates. Of particular concern are the possible effects of cumulative exposure. 
 
In a 2007 survey of personal care products available in Canada, phthalates were found in a wide 
range of products including those marketed for infant skin care (Koniecki et al., 2011). Of the 252 
personal care and cosmetic products tested 39% contained phthalates. The specific phthalates detected 
included; diethyl phthalate (DEP), dimethyl phthalate (DMP), diisobutyl phthalate (DiBP), di-n-butyl 
phthalate (DnBP) and di (2-ethylhexyl) phthalate (DEHP). 
 
Using data obtained from the Canadian Healthy Infant Longitudinal Development (CHILD) Study 
urine phthalate metabolites in 5000 three-month old infants was found to be associated with household 
use of tile cleaning agents; air fresheners; plastic storage containers and utensils used for breast milk, 
infant formula, food and beverages; infant skin care products, including baby wipes; and co-sleeping, due 
possibly to parent use of phthalate containing personal care products (Shu, 2010). 
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Table 1 
 
Phthalates identified for review and possible review by Environment Canada 
1
 
 
Dicyclohexyl phthalate 
Butyl cyclohexyl phthalate 
Diisobutyl phthalate 
Dimethyl phthalate 
Dibenzyl phthalate 
Diundecyl phthalate 
Cyclohexyl isobutyl phthalate 
Benzyl 3-isobutyryloxy-1-isopropyl-2,2-dimethylpropyl phthalate 
Diisodecyl phthalate 
Benzyl 2-ethylhexyl phthalate 
Bis(methylcyclohexyl) phthalate 
Diisononyl phthalate 
Benzyl octyl phthalate 
Diisoheptyl phthalate 
Diethyl phthalate 
Dibutyl phthalate [di-n-butyl phthalate]
3
 
Dihexyl phthalate 
Butyl benzyl phthalate 
Dioctyl phthalate [di(2-eythlexyl) phthalate]
2
 
Dipropyl phthalate 
Diallyl phthalate 
Diisooctyl phthalate 
Ditridecyl phthalate 
(C9-C11)Dialkyl phthalate 
Mixed hexyl, octyl, decyl phthalates 
Heptyl nonyl phthalate, branched and linear 
Branched and linear nonyl undecyl phthalate 
 
1
 (EC, 2013), 
2
 (NRC, 2008), 
3
 (Koniecki et al., 2011) 
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Appendix B: Transepidermal water loss and skin capacitance measurement 
Kottner, Lichterfeld and Blume-Peytavi (2013) describe TEWL as a critical aspect of skin barrier 
function. Measurement is a routine practice in dermatology practice and research and can provide 
accurate and reliable results. Evaporimeters measure the density of the flow of condensed water from 
deeper layers to the surface of the skin in grams per metre squared per hour. While a normal range for 
TEWL has not been identified, there is good evidence increased TEWL is associated the barrier function 
of the SC layer. Lower values indicate intact or healed skin, while elevated levels are associated with skin 
barrier defects (Kottner et al., 2013). TEWL is also affected by anatomical site, skin surface temperature, 
exertion, emotion, as well as air convection near the skin, direct light, ambient temperature and humidity, 
season, and geographical area (Pinnagoda et al.,1990; Kottner, Lichterfeld, & Blume-Peytavi, 2013). An 
open chamber evaporimeter measures TEWL in open air, in a non-invasive manner. Ambient room 
conditions must have little influence on the 10mm vapour layer that envelopes the skin to produce valid 
readings (Pinnagoda, J., Tupker, R.A., Agner, T., & Serup, J., 1990). Results are also highly influenced 
by technician training. Procedures involve placing the evaporimeter probe onto the skin, parallel to the 
skin surface with the contact pressure kept low but constant for as short a period as possible 
(approximately 30-45 seconds). Skin affected by AD lesions requires a longer measurement interval. 
Anatomical sites for TEWL assessment should be standardized. Room temperature should be kept 
between 20 to 22 
o
C with relative humidity and 40%. It is preferred, when practical, to complete all 
measurements within one season (Pinnagoda, J., Tupker, R.A., Agner, T., & Serup, J., 1990). Seidenari 
and Giusti (1995) showed a significant difference in TEWL could be detected using an evaporimeter 
between the skin of healthy children, intact skin of children with AD and lesional skin of children with AD 
in a sample of 100 children with AD and 21 without (Seidenari, S. & Giusti, G., 1995). 
 
Skin capacitance measures the electrical conductivity of the SC. The higher the water content of 
skin, the higher the capacitance. Capacitance is a measure of the amount of electrical charge that a 
substance can hold. Corneometers measure capacitance with a non-invasive electrical probe that is 
applied to the surface of skin.  Measurements are obtained within 1 to 1.5 seconds. The skin capacitance 
ATOPIC DISEASE PREVENTION— A RESEARCH SCHEMA FOR EVALUATING SKIN BARRIER 
PROTECTION AND PHTHALATE EXPOSURE REDUCTION     33 
 
LINDA KIRSTE 
value provided by a corneometer is given in arbitrary units from 0 to 120 (Gabard, Clarys & Barel, 2006). 
Seidenari & Giusti (1995) showed skin capacitance varies significantly between the skin of healthy 
children, intact skin of children with AD and lesional skin of children with AD when the mean capacitance 
values from eight different anatomical sites is compared. 
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Appendix C: Petrolatum-based moisturizers 
Natural petrolatum is a mixture of crystalline and liquid hydrocarbons derived from petroleum, 
with a general carbon chain length over C25  (European Commission, N.D.). It is derived by de-waxing the 
residual oil extracted from petroleum through a number of refining and purification steps. Purification 
includes removal of polycyclic aromatic hydrocarbons (PAHs) that are thought to be carcinogenic in rats 
(Rawlings & Lombard, 2012; Nash, Gettings, Diembeck, Chudowski & Kraus, 1996). Chronic topical 
exposure to natural white petrolatum has been deemed to lack health risk based on the long history of 
use and absence of toxicological findings in animals and humans (Nash et al., 1996). 
 
More recently, while rare, case reports have documented allergic contact dermatitis from 
petrolatum. PAHs contamination is thought to be responsible (Tam & Elston, 2006), with evidence of an 
epigenetic mechanism (Pacheco, 2012). Testing with various petrolatum products suggests the ability to 
sensitize is a brand specific phenomenon. Case reports also suggest allergic contact dermatitis may be 
restricted to damaged rather than intact skin (Tam & Elston, 2006). There are four types of petrolatum: 
natural, artificial, gatsch and synthetic. Natural, artificial and gatsch are derivatives of petroleum, while 
synthetic is manufactured through carbon monoxide hydrogenation of synthetic hydrocarbons. 
Considered free of PAHs, use of synthetic petrolatum may ensure prevention of allergic sensitization from 
petrolatum (Tam & Elston, 2006).   
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Appendix D: Proposed definition of incident AD 
“A history of an itchy skin condition that is either continuous or intermittent lasting at least four weeks plus 
three or more of the following: 
1. A history of a rash in the skin creases (folds of elbows, behind the knees, fronts of ankles, or around 
the neck) or on the extensor aspects of the forearms or lower legs 
2. A personal history of asthma or hay fever or a history of atopic disease in a first-degree relative 
3. A history of a generally dry skin since birth 
4. Visible flexural dermatitis and/or visible dermatitis on the forearms or lower legs with absence of 
auxiliary involvement as defined by our online photographic protocol” (Simpson et al., 2012). 
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Appendix E: Other exposures 
Irritants 
Dermal irritant exposure can increase TEWL and contribute to skin inflammation particularly in 
AD prone individuals. Irritants provoke skin inflammation without inducing antibody production (Beltrani et 
al, 2006; Chew & Maibach 2006). In normal skin they produce an initial increase in TEWL, but after longer 
term exposure functional adaptation within the skin leads to normalization of TEWL through up-regulation 
of ceramide production. This adaptive process is impaired among individuals who are prone to AD 
(Slowdownik, Lee & Nixon,  2008). 
 
Irritants comprise a vast array of chemical and mechanical exposures (Beltrani et al., 2006). They 
include detergents, solvents, oils, heat, dusts and fibres, acids and alkalis, friction, occlusion pressure, 
vibration and prolonged water exposure. The irritant effects of two or more substances may be additive or 
synergistic (Slowdownik et al.,  2008).  
 
Direct measurement of irritant exposure is problematic owing to the vast array of common irritants 
and the invasiveness of procedures to assess them (Wester, 2006). Exposure measurement may also be 
accomplished indirectly by employing validated questionnaires designed to collect infant skin care product 
usage data (Sathyanarayana et al., 2008). 
 
Bisphenol A 
Bisphenol A (BPA) is a synthetic compound used to harden polycarbonate plastics, epoxy resins, 
and to coat the inside of food and beverage containers and thermal paper (National Institutes of Health, 
2013). Like phthalates, BPA leaches into water and food over time, particularly when subjected to heat. 
Exposure appears to be wide spread, although research on the health effects of BPA is limited (Meeker, 
Sathyanarayana, & Swan, 2009). Concern has been raised over the possible effects on neurological and 
reproductive development (U.S. Department of Health & Human Services, 2013b). In an observational 
study, urine BPA levels above the mean obtained from pregnant women were positively associated with 
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wheezing among infants at six months of age after adjustment for other exposures (OR =  2.3, 95% CI: 
1.3-4.1). This suggests the possibility that BPA may be involved with the development of asthma and 
should be controlled for when investigating the relationship between phthalate exposure and the 
development of atopic diseases. BPA exposure may be measured by analysing urine concentrations 
(Spanier et al., 2012). 
 
Environmental Allergens 
Since the majority of time spent is within the home setting (Wu & Takaro, 2007), allergens 
commonly found indoors represent an important source of environmental exposure. Household inspection 
(Jaakkola, Quansah, Hugg, Heikkinen, & Jaakkola,  2013) and air sampling may be used to assess fungal 
exposures, while collection of dust from floors, furniture and linen may be analyzed to measure exposure 
to house dust, dust mite, animal and cockroach allergens (Gent et al., 2012). 
 
Numerous studies have shown AD skin lesions can be provoked through the dermal application 
of a variety of environmental allergens; including pollen, fungi, dust mite and pet allergens (Boralevi et al., 
2008; Capristo, Romei, & Boner, 2004). In a cross-sectional study, Boralevi and colleagues found infants 
three to 12 months of age with AD exhibited a higher prevalence of aeroallergen sensitization compared 
to controls without AD. Data from another cross-sectional study suggested AD symptom severity was 
associated with higher levels of air borne grass pollen (Krämer et al., 2005). In contrast, Asher and 
colleagues, in a summary of ISAAC Phase I results of ecological data, found no relationship between 
pollen exposure and eczema prevalence (Asher et al., 2010), suggesting the relationship between pollen 
exposure and AD is incomplete. 
 
Cat exposure seems to increase risk while dog exposure may be protective against AD 
development (Ownby & Johnson, 2011). Ownby &Johnson (2011) point out failure to find a strong 
relationship may have in part been due to the population studied. In a prospective study of infants with 
filaggrin mutations (Bisgarrd et al., 2008), a cat in the home strongly increased the hazard ratio for AD at 
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one year of age (HR = 11.1, 95% CI: 3.79-32.6). The authors speculated the effect of cat ownership may 
be mediated though a yet unknown factor for which cat exposure is a surrogate indicator. 
 
The relationship between asthma and environmental allergens also does not appear to be entirely 
clear. A meta-analysis of six studies suggests experimental reduction in household dust from birth is 
effective in asthma prevention between one to eight years of age (MacDonald, Sternberg, & Hunter, 
2007). A systematic review of nine intervention studies in which exposure to either environmental and/or 
dietary allergens was implemented indicated multi (both environmental and dietary allergen reduction) 
rather than single interventions were protective in children under five years (OR = 0.72, 95% CI: 0.54-
0.96) and over five years (OR = 0.52, 95% CI: 0.32-0.85). 
 
Jaakkola and colleagues (2013) conducted a systematic review and meta-analysis of studies to 
examine the relationship between mould exposure and rhinitis. Risk of allergic rhinitis was increased 
significantly with visible mould in the home (OR = 1.51, 95% CI: 1.39-1.64), but not mould odour. 
 
Environmental exposure to food allergens  
Cutaneous exposure to food allergens can induce atopic sensitization (Spergel et al., 1998). Lack 
(2008) suggested low dose dermal exposure to food proteins, inevitably present on a variety of household 
surfaces, penetrates the skin barrier provoking a Th2 sensitizing response. Food allergens have been 
shown to persist on household surfaces, including in pillow and furniture coverings even after cleaning. 
Brough et al. (2013) showed peanut protein exposure may be quantified from household dust samples. 
 
Environmental tobacco smoke  
Aside from being clearly associated with risk for asthma (Ciaccio & Gentile, 2013), environmental 
tobacco smoke (ETS) is thought to be an important predictor of AD development. Wang and colleagues 
found prenatal ETS exposure was positively associated with physician ever-diagnosed AD at two years of 
age. ETS exposure may increase the production of TSLP and thus induce a more intensely skewed Th2 
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inflammatory response within the skin (Wang, Chen, Lu, Chuan, & Chen, 2013). There is also evidence 
ETS increases the risk of IgE antibody sensitization (Ciaccio & Gentile, 2013). Pre and postnatal ETS 
exposure may be measured using validated questionnaire instruments; however urine cotinine appears to 
be a more sensitive measure of childhood exposure, particularly longitudinally (Puig et al., 2008). 
 
Microbial exposures  
Different human environments, from urban child care centres to rural working farms, are 
associated with contrasting household microbiomes. Prospective observational studies suggest child care 
centre attendance during the first six months of life, the presence of older siblings in the home (Ball et al., 
2000) and dwelling on farms during childhood is protective against asthma and allergy (von Mutius & 
Vercelli 2010). Experimental measures to reduce household microbial exposures have been associated 
with increased rates of allergic sensitization (Woodcock et al., 2004). Protective factors may include 
environmental exposure to farm animals, hay or grain products as early as during pregnancy, according 
to a cross-sectional study which found a dose-response relationship (Douwes et al., 2008). Maier et al. 
(2010) showed house dust sample microbial profiles predict the infant’s immediate environment including 
animal exposure and daycare attendance. The marker for microbial exposure used in many of these 
studies has been endotoxin, a lipopolysaccharide cell-well component of gram-negative bacteria. It has 
been demonstrated to have a strong capacity to promote Th1 over Th2 response immune responses 
(Bolte et al.,2003). In sum, these data suggest the bacterial communities of the home environment can be 
measured and are important predictors of atopic outcomes. 
 
Gastrointestinal microbiome 
Experimental studies in an effort to manipulate gastrointestinal bacterial flora have been under 
taken to explore their effects on atopic disease development. A 2013 meta-analysis of 25 double blinded 
placebo controlled randomized trials found probiotics were effective against atopic sensitization early in 
life (defined as either or both positive skin prick tests and elevated specific serum IgE antibody levels) 
when given pre and postnatally (RR=  0.88, 95% CI: 0.78-0.00), but not against asthma incidence (Elazab 
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et al., 2013). Analysis restricted to trials exploring the effect of pre- pro- and synbiotics on eczema 
prevention yielded 17 studies. Probiotics taken by the mother reduced AD risk (OR = 0.69, 95% CI: 62-
78). Significant effects were only detected when multiple bacterial strains were trialed (Dang et al., 2013). 
 
Timing and type of complementary foods 
Breast milk when compared to formula feeding appears to be protective against AD among 
children with a family history of atopy (OR = 0.58, 95% CI: 0.41-0.92) (Gdalevich, Mimouni, David, & 
Mimouni, 2001), but not against other atopic diseases. Age of introduction of solids is also associated 
with atopy risk (Greer, F.R., Sicherer, S.H., Burks, A.W. & The American Academy of Pediatrics 
Committee on Nutrition; American Academy of Pediatrics Section on Allergy and Immunology., 2008). 
(DuToit and colleages (2008) found an association between age of peanut ingestion and peanut allergy 
after adjusting for multiple factors, including family atopic history. 
 
Nutrition  
Numerous efforts have been undertaken to explore the relationship between the quality of early 
nutrition, beginning in utero, and the risk for atopic diseases. Prescott (2013) has summarized them, 
including findings that a maternal diet during pregnancy rich in ω-3 polyunsaturated fatty acids (fish oils) 
is associated with reduced incidence of AD and atopic sensitization during infancy. Similarly a 
Mediterranean diet, rich in fish, legumes, vegetables and fruits during pregnancy is associated with 
protection against atopy, including asthma in childhood (Nurmatov, Devereux, & Sheikh, 2011; Prescott, 
2013). The effects of vitamin D status have also been studied. However, isolating the effects of vitamin D 
status on the incidence is complicated by concurrent endogenous production of vitamin D triggered by 
exposure to sunshine. A meta-analysis on nutrient intake and allergic diseases found insufficient studies 
were available to draw conclusions on the relationship between vitamin D and atopic diseases other than 
that high intake during pregnancy was protective against childhood wheezing (OR = 0.56, 95% CI: 0.42-
0.73; OR = 0.66, 95% CI; 0.52-0.88 respectively), but not asthma (Nurmatov et al., 2011). 
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Prenatal folic acid supplementation has been associated with epigenetic changes that may 
contribute to risk of asthma (Jiefte-de Jong  et al., 2012). A meta-analysis however of folic acid intake 
during the first trimester of pregnancy did not find an association with the incidence of asthma in 
childhood. Heterogeneity of studies prevented conclusions from being drawn on associations with other 
atopic outcomes (Crider et al., 2013). Hence, there remains considerable controversy over the effect of 
diet quality and intakes of individual nutrients on atopic disease risk. It would thus seem prudent to 
monitor key aspects of dietary intakes during the proposed intervention study utilizing validated 
questionnaire instruments in a retrospective manner during pregnancy and in a prospective manner 
during infancy. 
   
Climate 
Conclusions drawn from ISAAC I suggest climatic conditions are associated with AD prevalence. 
Degrees latitude have been positively associated, while mean annual temperature negatively with 
prevalence. Design limitations prevent the independent assessment of the effect of sun exposure 
(Weiland,  et al., 2004). Data from the 2007 National Survey of Children’s Health study, suggests high 
mean annual relative humidity is protective, while prolonged annual requirement for indoor heating 
increases risk of AD (Silverberg, Hanifin, & Simpson, 2013). 
 
In an experimental study in which children with severe AD were randomized to relocate from 
Norway to the Grand Canary Islands for four weeks, AD severity decreased dramatically and remained 
improved for three months, indicating exposure to a subtropical climate is associated with better AD 
control (Byremo, Rød, & Carlsen, 2006), however the study was unable to control for other exposures 
associated with the intervention, such as the vacation experience. In another experimental study, the 
effect of temperature and air flow on skin barrier integrity did not change TEWL significantly unless 
sodium lauryl sulphate (a known skin irritant) was applied to the skin of healthy adults for 30 minutes 
(Fluhr et al., 2005). In sum these studies suggest it is important to control for climate in studies aimed at 
the primary prevention of AD and other atopic diseases.  
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